Safety, efficacy and immunogenicity of autologous tumor lysate-pulsed dendritic cell therapy after resection of stage2A (T2N0,T3N0) esophageal cancer
Not Applicable
- Conditions
- Esophageal cancer
- Registration Number
- JPRN-UMIN000002837
- Lead Sponsor
- The University of Tokyo Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who have: -Pulmonary fibrosis or interstitial pneumonia, including their history or predisposition; -Serious drug allergy; -Difficult infections to control; -Serious cardiac diseases; -Active autoimmune diseases; -Other cancers; -Continuous systemic administration of steroids and/or immunosuppressants within 4 weeks.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety
- Secondary Outcome Measures
Name Time Method Immunological responses Recurrence rate Recurrence-free survival Overall survival Survival rate Response of tumor-related markers